Americana Partners LLC Acquires Shares of 57,176 Catalent, Inc. (NYSE:CTLT)

Americana Partners LLC bought a new position in shares of Catalent, Inc. (NYSE:CTLT - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 57,176 shares of the company's stock, valued at approximately $2,569,000.

Other institutional investors also recently modified their holdings of the company. Thompson Siegel & Walmsley LLC boosted its holdings in shares of Catalent by 46.6% during the third quarter. Thompson Siegel & Walmsley LLC now owns 704,322 shares of the company's stock worth $32,069,000 after purchasing an additional 223,944 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Catalent by 1.8% during the third quarter. Vanguard Group Inc. now owns 20,468,027 shares of the company's stock worth $931,909,000 after purchasing an additional 365,648 shares during the period. Tran Capital Management L.P. raised its stake in Catalent by 12.2% in the fourth quarter. Tran Capital Management L.P. now owns 361,846 shares of the company's stock worth $16,258,000 after buying an additional 39,208 shares in the last quarter. Hsbc Holdings PLC raised its stake in Catalent by 43.1% in the third quarter. Hsbc Holdings PLC now owns 193,322 shares of the company's stock worth $8,803,000 after buying an additional 58,240 shares in the last quarter. Finally, SG Americas Securities LLC raised its stake in Catalent by 240.0% in the fourth quarter. SG Americas Securities LLC now owns 40,249 shares of the company's stock worth $1,808,000 after buying an additional 28,410 shares in the last quarter.

Catalent Stock Performance

Shares of Catalent stock traded down $0.21 on Friday, hitting $56.75. 1,099,014 shares of the company's stock were exchanged, compared to its average volume of 1,880,345. The company has a 50-day simple moving average of $56.63 and a 200-day simple moving average of $47.52. The stock has a market capitalization of $10.26 billion, a PE ratio of -8.35, a PEG ratio of 6.12 and a beta of 1.20. Catalent, Inc. has a 1 year low of $31.45 and a 1 year high of $67.54. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.73 and a current ratio of 2.48.

Catalent (NYSE:CTLT - Get Free Report) last released its earnings results on Friday, February 9th. The company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.22). Catalent had a negative net margin of 29.91% and a negative return on equity of 2.43%. The firm had revenue of $1.03 billion for the quarter, compared to analysts' expectations of $1.01 billion. During the same quarter last year, the firm posted $0.62 EPS. The firm's quarterly revenue was down 10.2% compared to the same quarter last year. As a group, equities analysts anticipate that Catalent, Inc. will post 0.28 EPS for the current year.

Analyst Upgrades and Downgrades

CTLT has been the subject of a number of research reports. UBS Group reissued a "neutral" rating and issued a $63.50 price target (up from $58.00) on shares of Catalent in a research note on Tuesday, February 6th. Royal Bank of Canada reissued a "sector perform" rating and issued a $63.50 price target on shares of Catalent in a research note on Tuesday, February 20th. Barclays increased their price target on shares of Catalent from $45.00 to $47.00 and gave the stock an "equal weight" rating in a research note on Thursday, January 25th. Stephens reissued an "equal weight" rating and issued a $63.50 price target on shares of Catalent in a research note on Thursday. Finally, StockNews.com initiated coverage on shares of Catalent in a research note on Wednesday. They issued a "sell" rating for the company. Two analysts have rated the stock with a sell rating, nine have given a hold rating and three have given a buy rating to the company's stock. According to data from MarketBeat.com, Catalent presently has a consensus rating of "Hold" and a consensus price target of $52.46.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.